Plant Vaccines: An Immunological Perspective

  • D. C. Hooper
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 332)

The advent of technologies to express heterologous proteins in planta has led to the proposition that plants may be engineered to be safe, inexpensive vehicles for the production of vaccines and possibly even vectors for their delivery. The immunogenicity of a variety of antigens of relevance to vaccination expressed in different plants has been assessed. The purpose of this article is to examine the utility of plant-expression systems in vaccine development from an immunological perspective.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE (2000) Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. Curr Pharm Des 6:261–276PubMedCrossRefGoogle Scholar
  2. CDC (2002) General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Mort Morbid Wkly Rep 51(RR02):1–36Google Scholar
  3. Choe NW, Estes MK, Langridge WH (2006) Synthesis of a ricin toxin B subunit-rotavirus VP7 fusion protein in potato. Mol Biotechnol 32:117–128CrossRefGoogle Scholar
  4. Choi NW, Esters MK, Langridge WH (2006) Ricin Toxin B subunit enhancement of rotavirus NSP4 immunogenicity in mice. Viral Immunol 19:54–63PubMedCrossRefGoogle Scholar
  5. Cohen-Kaminsky S, Jambou F (2005) Prospects for a T-cell receptor vaccination against myasthe-nia gravis. Expert Rev Vaccines 4:473–492PubMedCrossRefGoogle Scholar
  6. Cui Z, Qiu F (2006) Synthetic double-stranded RNA poly (I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol Immunother 55:1267–1279PubMedCrossRefGoogle Scholar
  7. Diebold SS, Plank C, Cotton M, Wagner E, Zenke M (2002) Mannose receptor-mediated gene delivery into antigen presenting dendritic cells. Somat Cell Mol Genet 27:65–74PubMedCrossRefGoogle Scholar
  8. Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI, Dalgleish AG (2002) Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 168:4914–4919PubMedGoogle Scholar
  9. Faria AM, Weiner HL (2005) Oral tolerance. Immunol Rev 206:232–259PubMedCrossRefGoogle Scholar
  10. Fujihashi K, Koga T, van Ginkel FW, Hagiware Y, McGhee JR (2002) A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20:2431–2438PubMedCrossRefGoogle Scholar
  11. Gleba Y, Klimyuk V, Marillonnet S (2005) Magnification-a new platform for expressing recom-binant vaccines in plants. Vaccine 23:2042–2048PubMedCrossRefGoogle Scholar
  12. Gustafson GL, Rhodes MJ (1992) Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res Immunol 143:483–488PubMedCrossRefGoogle Scholar
  13. Hanlon CA, DeMattos CA, DeMattos CC, Niezgoda M, Hooper DC, Koprowski H, Notkins A, Rupprecht CE (2001) Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis. Vaccine 19:3834–3842PubMedCrossRefGoogle Scholar
  14. Helm RM, Furuta GT, Stanley JS, Ye J, Cockrell G, Connaughton C, Simpson P, Bannon GA, Burks AW (2002) A neonatal swine model for peanut allergy. J Allergy Clin Immunol 109:136–142PubMedCrossRefGoogle Scholar
  15. Jalava K, Eko FO, Riedmann E, Lubitz W (2003) Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Rev Vaccines 2:45–51PubMedCrossRefGoogle Scholar
  16. Jenner E (1798) An inquiry into the causes and effects of the variolae vaccine. London: printed for the author by Sampson LawGoogle Scholar
  17. Keller MA, Stiehm ER (2000) Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 13:602–614PubMedCrossRefGoogle Scholar
  18. Ko K, Tekoah Y, Rudd PM, Harvey DJ, Dwek RA, Spitsin S, Hanlon CA, Rupprecht C, Dietzschold B, Golovkin M, Koprowski H (2003) Function and glycosylation of plant-derived antiviral monoclonal antibody. Proc Natl Acad Sci U S A 100:8013–8018PubMedCrossRefGoogle Scholar
  19. Ko K, Steplewski Z, Glogowska M, Koprowski H (2005) Inhibition of tumor growth by plantderived mAb. Proc Natl Acad Sci U S A 102:7026–7030PubMedCrossRefGoogle Scholar
  20. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709–760PubMedCrossRefGoogle Scholar
  21. Kumpel BM (2002) On the mechanism of tolerance to the Rh D antigen mediated by passive anti-D (Rh D prophylaxis). Immunol Lett 82:67–73PubMedCrossRefGoogle Scholar
  22. Lenarczyk A, Le TT, Drane D, Malliaros J, Pearse M, Hamilton R, Cox J, Luft T, Gardner J, Suhrbier A (2004) ISCOM based vaccines for cancer immunotherapy. Vaccine 22:963–974PubMedCrossRefGoogle Scholar
  23. Li ZG, Mu R, Dai ZP, Gao XM (2005) T cell vaccination in systemic lupus erythematosus with autologous activated T cells. Lupus 14:884–889PubMedCrossRefGoogle Scholar
  24. Lyche N (2005) Targeted vaccine adjuvants based on modified cholera toxin. Curr Mol Med 5:591–597CrossRefGoogle Scholar
  25. Pasteur L (2002) Summary report of the experiments conducted at Pouilly-le-Fort Near Melun, on the anthrax vaccination. Classics of Biology and Medicine. Yale J Biol Med 75:59–62PubMedGoogle Scholar
  26. Ramon G, Zoeller C (1927) L'anatoxine tétanique et l'immunisation active de l'homme vis-à-vis du tétanos. Ann Inst Pasteur 41:803–833Google Scholar
  27. Robinson JH, Delvig AA (2002) Diversity in MHC class II antigen presentation. Immunology 105:252–262PubMedCrossRefGoogle Scholar
  28. Sawyer LA (2000) Antibodies for the prevention and treatment of viral diseases. Antiviral Res 47:57–77PubMedCrossRefGoogle Scholar
  29. Schijns VE (2001) Induction and direction of immune responses by vaccine adjuvants. Crit Rev Immunol 21:75–85PubMedGoogle Scholar
  30. Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425(6957):516–521PubMedCrossRefGoogle Scholar
  31. Vandenbark AA, Morgan E, Bartholomew R, Bourdette D, Whitham R, Carlo D, Gold D, Hashim G, Offner H (2001) TCR peptide therapy in human autoimmune diseases. Neurochem Res 26:713–730PubMedCrossRefGoogle Scholar
  32. Verch T, Yusibov V, Koprowski H (1998) Expression and assembly of a full-length monoclonal antibody in plants using a plant virus vector. J Immunol Methods 220:69–75PubMedCrossRefGoogle Scholar
  33. Vichier-Guerre S, Lo-Man R, BenMohamed L, Deriaud E, Kovats S, Leclerc C, Bay S (2003) Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anticancer vaccine for human use. J Pept Res 62:117–124PubMedCrossRefGoogle Scholar
  34. Weinstein PD, Cebra JJ (1991) The preference for switching to IgA expression by Peyer's patch germinal center B cells is likely due to the intrinsic influence of their microenvironment. J Immunol 147:4126–4135PubMedGoogle Scholar
  35. Yusibov V, Hooper DC, Spitsin SV, Fleysh N, Kean RB, Mikheeva T, Deka D, Karasev A, Cox S, Randall J, Koprowski H (2002) Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 20:3155–3164PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • D. C. Hooper
    • 1
  1. 1.Associate Professor, Center for Neurovirology, Kimmel Cancer CenterThomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations